Microsomal prostaglandin E synthase-1 (mPGES1) (genetic determinant of early onset breast cancer and predisposition to cancers of the ovary, colon, prostate gland and Fallopian tubes) is the downstream enzyme in the prostaglandin pathway. Expression of mPGES1 is inducible in conditions of inflammation and hypoxia and its expression is regulated by a number of transcriptional factors. Clinical studies have shown increased levels of mPGES-1, associated with increased PGE2 production, within a number of human cancers, including colon, lung, stomach, pancreas, cervix, prostate, papillary thyroid carcinoma, head and neck squamous carcinoma, brain tumors and melanoma.
The “10132 – m-PGES1, Melanoma, TME” APP detects nuclei and classifies them as either negative, 1+, 2+ or 3+ based on the m-PGES1 staining expression present in each nucleus’ vicinity.